Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 19, 2012

Primary Completion Date

May 20, 2019

Study Completion Date

May 20, 2019

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

Bortezomib

Bortezomib will be given twice a week subcutaneously (under the skin) for two weeks in every 3 week cycle.

DRUG

Doxil

Doxil or LipoDox will also be given through a venous catheter (inside your vein). Doxil or LipoDox will be given over 60 to 90 minutes on Day 4 of every 21-day cycle.

Trial Locations (1)

95817

University of California Comprehensive Cancer Center, Sacramento

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Joseph Tuscano

OTHER

NCT01736943 - Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia | Biotech Hunter | Biotech Hunter